Lit Matters #2: Dalbavancin Lacks Economic or Efficacy Advantage for SSTIs

Dalbavancin does not appear to outperform standard antibiotics for acute bacterial skin and skin structure infections, and its upfront price is substantial. In this multisite SSTI study, single-dose dalbavancin was associated with higher net cost and more 30-day SSTI readmissions than standard care.

Dalbavancin for SSTI Value

• High acquisition cost: Dalbavancin carries a wholesale price around $4,600, so the real question is whether a one-dose strategy can replace hospitalization without sacrificing outcomes.
• No economic advantage: The study found a markedly higher net cost to the health system with dalbavancin than standard care, despite similar reimbursement per patient.
• Lower treatment success: Treatment success, defined as no SSTI-related readmission within 30 days, was lower with dalbavancin at 74% versus 85% with standard care.
• Readmission signal: Thirty-day SSTI-related readmissions were higher in the dalbavancin group, a practical outcome that undercuts the appeal of single-dose convenience.
• Possible niche subgroup: A treatment-naive subgroup showed an odds ratio favoring dalbavancin, but the broader results still leaned toward standard care. We get into where that exception may matter in the episode.